FDA Approves Daybue

FDA Approves Daybue (trofinetide) for the Treatment of Rett Syndrome SAN DIEGO–(BUSINESS WIRE)–Mar. 10, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. […]